Brind.
  1. Vivani Medical, Inc. is developing NPM-139 Semaglutide Implant, an ultra long-acting drug with potential Wegovy-level efficacy.

Novo Nordisk is evaluating Vivani's implant technology for weight management and health risks.

1 report, 1 independent Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Novo Nordisk is evaluating Vivani's implant technology for weight management and health risks.

Who's involved

What this event is mainly about
Novo NordiskAdam Mendelsohn

Keep exploring

Part of

Vivani Medical, Inc. is developing NPM-139 Semaglutide Implant, an ultra long-acting drug with potential Wegovy-level efficacy. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped